The impact of histological grade on outcomes in follicular lymphoma: An analysis of patients in the SEER database in the context of evolving disease classification and treatment. (16th August 2022)

• Record Type: Journal Article
• Authors: Naik, Anisha; Gooley, Ted; Loeb, Keith; Soma, Lorinda; Smith, Stephen D.; Gopal, Ajay; Naresh, Kikkeri N.
• Is Part Of: British journal of haematology. Volume 199:Number 5(2022)
• Page Start: 696
• Page End: 706
• Publication Date: 2022-08-16
• Subjects: follicular lymphoma -- grading -- rituximab -- survival; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.18404
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Currently, there is no convincing evidence that the grade of follicular lymphoma (FL) impacts patient outcome. We correlated grades in 33 925 patients with nodal FL during 1992–2018 in the SEER database with disease‐specific survival (DSS) and overall survival (OS). Patients with FL grade 3 had lower DSS and OS as compared to FL grades 1–2. During 1992–2005, the 10‐year DSS for patients with FL grades 3 and grades 1–2 were 68.6%, and 71.4%, respectively, and in 2006–2018, they were 77.7% and 82.6%, respectively. The 10‐year OS estimates in 1992–2005 were 49.9% and 54.2% for grade 3 and grades 1–2 respectively, and in 2006–2018, they were 59.1% and 63.5% for grade 3 and grades 1–2, respectively. After adjustment for stage and age, the hazard ratios for death due to FL and death from any cause for patients with FL grade 3 during 1992–2005 were 1.09 (1.02–1.16) and 1.07 (1.02–1.12), respectively, compared to FL grades 1–2; and during 2006–2018, the hazard ratios for death due to FL and death from any cause for patients with FL grade 3 were 1.34 (1.22–1.45) and 1.16 (1.10–1.23), respectively compared to FL grades 1–2. The grade of FL is an important determinant of disease biology.